<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-118010</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment of type 2 diabetes mellitus in patients with chronic kidney disease</dc:title>
<dc:description xml:lang="en">Chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) are highly prevalent chronic diseases, which represent an important public health problem and require a multidisciplinary management. T2DM is the main cause of CKD and it also causes a significant comorbidity with regard to non-diabetic nephropathy. Patients with diabetes and kidney disease represent a special risk group as they have higher morbi-mortality as well as higher risk of hypoglycemia than diabetic individuals with a normal kidney function. Treatment of T2DM in patients with CKD is controversial because of the scarcity of available evidence. The current consensus report aims to ease the appropriate selection and dosage of antidiabetic treatments as well as the establishment of safety objectives of glycemic control in patients with CKD (AU)</dc:description>
<dc:creator>Menéndez, Edelmiro</dc:creator>
<dc:creator>Górriz, José Luis</dc:creator>
<dc:creator>Martínez Castelao, Alberto</dc:creator>
<dc:creator>Artola, Sara</dc:creator>
<dc:creator>Gómez Huelgas, Ricardo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La enfermedad renal crónica (ERC) y la diabetes mellitus tipo 2 (DM2) son afecciones crónicas de elevada prevalencia que representan un importante problema de salud pública y requieren un abordaje interdisciplinario. La DM2 es la principal causa de ERC en nuestro medio y también constituye una importante comorbilidad de la nefropatía no diabética. Los pacientes con diabetes e insuficiencia renal son un grupo de especial riesgo, pues presentan una mayor morbimortalidad y un superior riesgo de hipoglucemias que los sujetos diabéticos con función renal normal. El tratamiento de la DM2 en los pacientes con ERC resulta controvertido dada la escasez de evidencias disponibles. El presente documento de consenso pretende facilitar la adecuada elección y dosificación de los fármacos antidiabéticos y el establecimiento de unos objetivos seguros de control glucémico en los pacientes con ERC (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);142(2): 85-85, ene. 2014.</dc:source>
<dc:identifier>ibc-118010</dc:identifier>
<dc:title xml:lang="es">Tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica</dc:title>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d3946^s22012</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d50497^s22012</dc:subject>
<dc:subject>^d50497^s22067</dc:subject>
<dc:subject>^d29627</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22101</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:type>article</dc:type>
<dc:date>201401</dc:date>
</metadata>
</record>
</ibecs-document>
